Want to see HRMY full AI Analyst Report?
HRMY Stock Chart & Stats
$29.99
-$1.07(-3.04%)
At close: 4:00 PM EST
$29.99
-$1.07(-3.04%)
Day’s Range― - ―
52-Week Range$25.52 - $40.87
Previous CloseN/A
Volume87.33K
Average Volume (3M)816.46K
Market Cap
$1.96B
Enterprise Value$1.21K
Total Cash (Recent Filing)$640.92M
Total Debt (Recent Filing)$206.51M
Price to Earnings (P/E)13.4
Beta1.03
Next Earnings
Aug 11, 2026EPS Estimate
0.92Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.52
Shares Outstanding57,892,677
10 Day Avg. Volume811,051
30 Day Avg. Volume816,462
Financial Highlights & Ratios
PEG Ratio1.74
Price to Book (P/B)2.47
Price to Sales (P/S)2.48
P/FCF Ratio6.18
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$46.25Price Target Upside54.22% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)3.46
Revenue Forecast (FY)$1.01B
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthExtremely low leverage and a large cash balance provide durable financial flexibility to fund commercialization, defend IP, and pursue M&A or pipeline investments. This reduces refinancing risk and supports multi-year plans for launches and BD even if revenue growth softens.
Cash Generation QualityOperating cash flow materially outpacing net income indicates high earnings quality and convertibility into cash. That steady cash generation underpins reinvestment in sales, clinical programs, and BD, enabling sustainable operations and reducing dependence on external capital over the medium term.
Durable Commercial FranchiseConsistent, sizable WAKIX revenues and improving quarterly records reflect a strong specialty commercial model, low current market penetration (~10–11%), and recent field expansion. These factors support multi-quarter revenue durability while new indications and formulations expand addressable markets.
Bears Say
Slowing Growth & Margin CompressionA marked slowdown from earlier high-growth years and compressed margins reduce free cash flow tailwinds and the company's optionality. If structural growth remains muted, Harmony may need sustained commercial investment or BD to meet long-term targets, pressuring profitability and capital allocation.
Rising COGS And Higher Operating CostsHigher COGS (royalties from new license) and elevated operating expenses—including one-time and recurring BD/license costs—apply structural pressure to gross and operating margins. Persistently higher cost base can erode cash flow and limit reinvestment unless offset by stronger revenue or margin remediation.
Legal, Access And Competitive RisksProtracted litigation and market-access friction create durable uncertainty around exclusivity and prescribing patterns. If appeals or ANDA outcomes erode protection, or if orexin competitors commercialize broadly, Harmony's pricing power and market share for WAKIX could face long-term pressure.
Harmony Biosciences Holdings News
HRMY FAQ
What was Harmony Biosciences Holdings, Inc.’s price range in the past 12 months?
Harmony Biosciences Holdings, Inc. lowest stock price was $25.52 and its highest was $40.87 in the past 12 months.
What is Harmony Biosciences Holdings, Inc.’s market cap?
Harmony Biosciences Holdings, Inc.’s market cap is $1.96B.
When is Harmony Biosciences Holdings, Inc.’s upcoming earnings report date?
Harmony Biosciences Holdings, Inc.’s upcoming earnings report date is Aug 11, 2026 which is in 21 days.
How were Harmony Biosciences Holdings, Inc.’s earnings last quarter?
Harmony Biosciences Holdings, Inc. released its earnings results on May 07, 2026. The company reported $0.55 earnings per share for the quarter, missing the consensus estimate of $0.695 by -$0.145.
Is Harmony Biosciences Holdings, Inc. overvalued?
According to Wall Street analysts Harmony Biosciences Holdings, Inc.’s price is currently Undervalued.
Does Harmony Biosciences Holdings, Inc. pay dividends?
Harmony Biosciences Holdings, Inc. does not currently pay dividends.
What is Harmony Biosciences Holdings, Inc.’s EPS estimate?
Harmony Biosciences Holdings, Inc.’s EPS estimate is 0.92.
How many shares outstanding does Harmony Biosciences Holdings, Inc. have?
Harmony Biosciences Holdings, Inc. has 57,892,677 shares outstanding.
What happened to Harmony Biosciences Holdings, Inc.’s price movement after its last earnings report?
Harmony Biosciences Holdings, Inc. reported an EPS of $0.55 in its last earnings report, missing expectations of $0.695. Following the earnings report the stock price went down -4.149%.
Which hedge fund is a major shareholder of Harmony Biosciences Holdings, Inc.?
Currently, no hedge funds are holding shares in HRMY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Harmony Biosciences Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$46.25 (54.22% Upside)
$46.25 (54.22% Upside)
Blogger Sentiment
Bullish
HRMY Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 142.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.5%
Last 30 Days ▲ 4.9%
Last 30 Days ▲ 4.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-7.30%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
20.49%
Trailing 12-Months
Company Description
Harmony Biosciences Holdings, Inc.
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.
HRMY Stock 12 Month Forecast
Average Price Target
$46.25
▲(54.22% Upside)
Technical Analysis
Ownership Overview
1.11% Insiders
20.89% Mutual Funds
0.34% Other Institutional Investors
47.54% Public Companies and
Individual Investors